Unravelling the cellular response to the SARS-COV-2 vaccine in inflammatory bowel disease patients on biologic drugs
-
Published:2023-12-27
Issue:1
Volume:13
Page:
-
ISSN:2045-2322
-
Container-title:Scientific Reports
-
language:en
-
Short-container-title:Sci Rep
Author:
Martínez-Domínguez Samuel J.,García-Mateo Sandra,Sainz-Arnal Pilar,Martínez-García Javier,Gallego-Llera Beatriz,Lozano-Limones María Jesús,Hidalgo Sandra,Gargallo-Puyuelo Carla J.,Latre-Santos Marta,Nocito-Colon Maria Mercedes Lourdes,Martínez-Lostao Luis,Refaie Engy,Arroyo-Villarino Maria Teresa,del Rio-Nechaevsky Marcela,Ramirez-Labrada Ariel,Pardo Julián,Gomollón Fernando,Baptista Pedro M.
Abstract
AbstractSuboptimal vaccine response is a significant concern in patients with Inflammatory Bowel Disease (IBD) receiving biologic drugs. This single-center observational study involved 754 patients with IBD. In Phase I (October 2020-April 2021), 754 IBD participants who had not previously received the SARS-CoV-2 vaccine, underwent blood extraction to assess the seroprevalence of SARS-CoV-2 infection and IBD-related factors. Phase II (May 2021-October 2021) included a subgroup of 52 IBD participants with confirmed previous SARS-CoV-2 infection, who were studied for humoral and cellular response to the SARS-CoV-2 vaccine. In Phase I, treatment with anti-TNF was associated with lower rates of seroconversion (aOR 0.25 95% CI [0.10–0.61]). In Phase II, a significant increase in post-vaccination IgG levels was observed regardless of biologic treatment. However, patients treated with anti-TNF exhibited significantly lower IgG levels compared to those without IBD therapy (5.32 ± 2.47 vs. 7.99 ± 2.59 U/ml, p = 0.042). Following vaccination, a lymphocyte, monocyte, and NK cell activation pattern was observed, with no significant differences between patients receiving biologic drugs and those without IBD treatment. Despite lower seroprevalence and humoral response to the SARS-CoV-2 vaccine in patients treated with anti-TNF, the cellular response to the vaccine did not differ significantly from that patients without IBD therapy.
Funder
European Regional Development Fund
Centro de Investigación Biotecnológica en Red de Enfermedades Infecciosas
Ministerio de Ciencia, Innovación y Universidades
Agencia Estatal de Investigación
Fundación Inocente, Inocente
Fundación Científica Asociación Española Contra el Cáncer
ASPANOA
Carrera de la mujer de Monzón
Diputación General de Aragón
Publisher
Springer Science and Business Media LLC
Subject
Multidisciplinary
Reference35 articles.
1. Kaplan, G. G. & Windsor, J. W. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 18, 56–66 (2021).
2. Reich, J., Wasan, S. & Farraye, F. A. Vaccinating patients with inflammatory bowel disease. Gastroenterol. Hepatol. 12, 540–546 (2016).
3. Coronavirus disease (COVID-19)—World Health Organization https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (2023).
4. Monteleone, G. & Ardizzone, S. Are patients with inflammatory bowel disease at increased risk for covid-19 infection?. J. Crohns Colitis 14, 1334–1336 (2020).
5. Sultan, K. et al. Corticosteroid and biologic use not associated with adverse outcomes for inflammatory bowel disease patients hospitalized with COVID-19. Gastroenterol. Res. 14, 324–333 (2021).